- Home
- GALT vs EICA Comparison
GALT vs EICA Comparison
Compare GALT & EICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | EICA |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | |
| Employees | 15 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | N/A |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GALT | EICA |
|---|---|---|
| Price | $3.06 | $24.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 326.5K | 3.0K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $24.00 |
| 52 Week High | $7.13 | $24.98 |
Technical Indicators
Market Signals| Indicator | GALT | EICA |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 52.47 |
| Support Level | $2.88 | $24.55 |
| Resistance Level | $3.27 | $24.85 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 32.79 | 43.61 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About EICA Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.